Bachem Stock - Analyst consensus and pipeline focus

Bachem stock remains driven by long-term demand for peptides and oligonucleotides while analyst consensus and earnings expectations set the tone. A look at current ratings, the order book and where the shares trade today.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 20:18 UTC. Details in the imprint.

Bachem (CH0012530207) remains a closely watched specialty chemicals and life-sciences stock in Switzerland. With no new market-moving company announcement today, the focus shifts to analyst consensus, expectations around peptide and oligonucleotide demand, and where the shares currently trade.

What analysts currently say

Recent data on financial portals show that Bachem is followed by a small but focused group of analysts, with ratings spread between Buy and Hold and hardly any outright Sell calls. Consensus expectations still price in meaningful medium-term growth from peptides and oligonucleotides.

Market data aggregators indicate that the average target price remains above the current market level, implying upside based on present estimates, even after past volatility in the shares. All told, the street appears cautiously optimistic but more selective than during the previous biotech upcycle.

Consensus, earnings and key risks

Analysts highlight that Bachem’s earnings profile is highly sensitive to large customer projects and capacity utilization at its peptide facilities. Delays in drug development pipelines at pharma customers can therefore move revenue and profit timing noticeably from one year to the next.

On balance, current models assume that capacity expansions and demand for complex peptides and oligonucleotides gradually support higher margins over the next several years. However, many houses also flag execution risk on new plants, regulatory inspections and potential pricing pressure from large clients.

The product behind the stock

Bachem focuses on contract development and manufacturing of active pharmaceutical ingredients, especially synthetic peptides and oligonucleotides used in drugs, diagnostics and research reagents. The company generates revenue mainly from long-term supply contracts with global pharmaceutical and biotech companies.

Where the stock trades today

The shares of Bachem (CH0012530207) most recently traded on SIX Swiss Exchange at CHF 65.00 as of 06/18/2026, 16:30 CET.

Key facts on Bachem stock

• Company: Bachem Holding AG
• ISIN: CH0012530207
• WKN: 907637
• Ticker: BANB
• Venue: SIX Swiss Exchange
• Price (as of 06/18/2026, 16:30 CET): 65.00 CHF
• Market cap: 4,400,000,000 CHF (as of 06/18/2026)
• Sector / Industry: Health Care - Pharmaceuticals, Biotechnology & Life Sciences
• Index membership: SPI
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.